drugset / Trial / NCT03939975

Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCC

NCT03939975 ↗

Phase 2 Completed 50 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

The inhibition of programmed cell death protein 1 (PD-1) has shown promising antitumor activity in advanced hepatocellular carcinoma (HCC). Unfortunately, less than 20% of HCC have response. The effect of PD-1 blockade and incomplete thermal ablation in patients with advanced HCC is not yet clearly understood. This study aimed to analyze outcomes of advanced HCC treated with anti PD-1 inhibitors in combination with incomplete thermal ablation.

Timeline

Start
2019-06-01
Primary completion
2019-07-31
Completion
2019-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Nivolumab Monoclonal antibody 3 mg/kg —
Subject Pembrolizumab Monoclonal antibody 2 mg/kg —
Subject Toripalimab Monoclonal antibody 240 mg —